Background: BRCA1/2 mutation status has increasing relevance for ovarian cancer treatments, making traditional coordination of genetic testing by genetic services unsustainable. Consequently alternative models of genetic testing have been developed to improve testing at the initial diagnosis for all eligible women. Methods: A training module to enable mainstreamed genetic testing by oncology healthcare professionals was developed by genetic health professionals. Oncology healthcare professionals completed questionnaires before and 12 months post-training to assess perceived skills, competence and barriers to their coordinating genetic testing for women with high-grade non-mucinous epithelial ovarian cancer. Genetic health professionals were...
The final publication is available at Springer via http://dx.doi.org/10.1007/s10897-017-0108-5Decrea...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
Background: Up to 20% of women diagnosed with tubo-ovarian carcinoma carry a germline pathogenic var...
The increasing use of genetic testing for BRCA1/2 and other pathogenic variants in the management of...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
According to current guidelines, all women with epithelial ovarian cancer are eligible for genetic t...
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances ...
<p><strong>Introduction: </strong>Identifying germline BRCA mutations in ovarian cancer patients is ...
PurposeThis study sought to determine genetics and oncology specialists' views of integrating BRCA1 ...
Decreasing costs of genetic testing and advances in treatment for women with cancer with germline $\...
BACKGROUND: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more ...
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances ...
Aim: To evaluate the extent of BRCA mutation testing in patients with ovarian cancer and their aware...
Mainstream genetic testing in routine oncology care requires implementation research to inform inter...
Objective: Pathogenic BRCA variants account for between 5.8-24.8% of ovarian cancers. The identifica...
The final publication is available at Springer via http://dx.doi.org/10.1007/s10897-017-0108-5Decrea...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
Background: Up to 20% of women diagnosed with tubo-ovarian carcinoma carry a germline pathogenic var...
The increasing use of genetic testing for BRCA1/2 and other pathogenic variants in the management of...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
According to current guidelines, all women with epithelial ovarian cancer are eligible for genetic t...
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances ...
<p><strong>Introduction: </strong>Identifying germline BRCA mutations in ovarian cancer patients is ...
PurposeThis study sought to determine genetics and oncology specialists' views of integrating BRCA1 ...
Decreasing costs of genetic testing and advances in treatment for women with cancer with germline $\...
BACKGROUND: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more ...
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances ...
Aim: To evaluate the extent of BRCA mutation testing in patients with ovarian cancer and their aware...
Mainstream genetic testing in routine oncology care requires implementation research to inform inter...
Objective: Pathogenic BRCA variants account for between 5.8-24.8% of ovarian cancers. The identifica...
The final publication is available at Springer via http://dx.doi.org/10.1007/s10897-017-0108-5Decrea...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
Background: Up to 20% of women diagnosed with tubo-ovarian carcinoma carry a germline pathogenic var...